A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
← catalyst calendarNCT06943833 · readout in 572 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
37actual
Sites
12
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-31 | actual | When the study began enrolling |
| Primary completion | 2028-03-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-13 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced Cervical Cancer
Intervention
- Biological: Volrustomig — also filed as MEDI5752
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival at 24 months (PFS24)
measured From date of first dose until 24 months.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed